Kastle Drug Patent Portfolio
Kastle owns 1 orange book drug protected by 8 US patents Given below is the list of Kastle's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7511131 | Antisense modulation of apolipoprotein B expression | 29 Jan, 2027 | Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines | 05 Sep, 2023 | Expired |
| US7015315 | Gapped oligonucleotides | 21 Mar, 2023 | Expired |
| US7407943 | Antisense modulation of apolipoprotein B expression | 01 Aug, 2021 | Expired |
| US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions | 26 Dec, 2017 | Expired |
| US6451991 | Sugar-modified gapped oligonucleotides | 11 Feb, 2017 | Expired |
| US5914396 | 2'-O-modified nucleosides and phosphoramidites | 22 Jun, 2016 | Expired |
| US6222025 | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom | 06 Mar, 2015 | Expired |
Latest Legal Activities on Kastle's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kastle.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 03 May, 2021 | US7511131 |
|
Maintenance Fee Reminder Mailed
Critical
| 16 Nov, 2020 | US7511131 |
|
Expire Patent
Critical
| 07 Sep, 2020 | US7407943 |
|
Maintenance Fee Reminder Mailed
Critical
| 23 Mar, 2020 | US7407943 |
|
Email Notification
Critical
| 09 Jan, 2017 | US7511131 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Jan, 2017 | US7511131 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Jan, 2017 | US7407943 |
|
Email Notification
Critical
| 09 Jan, 2017 | US7407943 |
|
Correspondence Address Change
Critical
| 06 Jan, 2017 | US7511131 |
|
Correspondence Address Change
Critical
| 06 Jan, 2017 | US7407943 |
|
Patent Term Extension Certificate
Critical
| 13 Dec, 2016 | US7511131 |
| Notice of Final Determination -Eligible | 13 Sep, 2016 | US7511131 |
| Notice of Final Determination -Eligible | 25 Aug, 2016 | US7511131 |
|
FDA Final Eligibility Letter
Critical
| 30 Nov, 2015 | US7511131 |
| transaction for FDA Determination of Regulatory Review Period | 21 Apr, 2015 | US7511131 |
Kastle's Drug Patent Litigations
Kastle's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 18, 2000, against patent number US7015315. The petitioner , challenged the validity of this patent, with COOK et al as the respondent. Click below to track the latest information on how companies are challenging Kastle's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7015315 | September, 2004 |
Decision
(27 Apr, 2005)
| COOK et al | |
| US7015315 | October, 2000 |
Decision
(31 Oct, 2002)
| COOK et al | |
Kastle's Family Patents
Kastle Drug List
Given below is the complete list of Kastle's drugs and the patents protecting them.
1. Kynamro
Kynamro is protected by 8 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7511131 | Antisense modulation of apolipoprotein B expression |
29 Jan, 2027
(1 year, 20 days from now)
| Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines |
05 Sep, 2023
(2 years ago)
| Expired |
| US7015315 | Gapped oligonucleotides |
21 Mar, 2023
(2 years ago)
| Expired |
| US7407943 | Antisense modulation of apolipoprotein B expression |
01 Aug, 2021
(4 years ago)
| Expired |
| US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
26 Dec, 2017
(8 years ago)
| Expired |
| US6451991 | Sugar-modified gapped oligonucleotides |
11 Feb, 2017
(8 years ago)
| Expired |
| US5914396 | 2'-O-modified nucleosides and phosphoramidites |
22 Jun, 2016
(9 years ago)
| Expired |
| US6222025 | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
06 Mar, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kynamro's drug page